Viridian Therapeutics, Inc. (VRDN) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
VRDN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
VRDN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -512.9% | -483.6% |
| 2024 | 100.0% | -99018.2% | -89387.1% |
| 2023 | 100.0% | -81035.0% | -75711.5% |
| 2022 | 100.0% | -7579.2% | -7329.2% |
| 2021 | 100.0% | -2690.8% | -2680.2% |
Download Data
Export VRDN earnings history in CSV or JSON format
Free sign-in required to download data
Viridian Therapeutics, Inc. (VRDN) Earnings Overview
As of May 8, 2026, Viridian Therapeutics, Inc. (VRDN) reported trailing twelve-month net income of -$361M, reflecting +16.6% year-over-year growth. The company earned $-3.53 per diluted share over the past four quarters, with a net profit margin of -483.6%.
Looking at the long-term picture, VRDN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2013.
Viridian Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), RDVT ($14M net income, 14.6% margin), KYMR (-$315M net income, -794.4% margin), VRDN has comparable earnings metrics. Compare VRDN vs IMVT →
VRDN Earnings vs Peers
Earnings metrics vs comparable public companies
VRDN Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$343M | -26.9% | -$363M | $-3.32 | -483.6% | -512.9% |
| 2024 | -$270M | -13.6% | -$299M | $-3.98 | -89387.1% | -99018.2% |
| 2023 | -$238M | -83.0% | -$254M | $-5.31 | -75711.5% | -81035.0% |
| 2022 | -$130M | -63.5% | -$134M | $-3.91 | -7329.2% | -7579.2% |
| 2021 | -$79M | +28.3% | -$80M | $-6.66 | -2680.2% | -2690.8% |
| 2020 | -$111M | -164.4% | -$110M | $-31.20 | -10544.3% | -10512.4% |
| 2019 | -$42M | -28.0% | -$42M | $-20.31 | -938.6% | -941.0% |
| 2018 | -$33M | -23.4% | -$33M | $-16.57 | -390.0% | -394.5% |
| 2017 | -$27M | -109.2% | -$27M | $-20.66 | -662.3% | -662.8% |
| 2016 | -$13M | -11.9% | -$13M | $-17.57 | -379.8% | -374.8% |
See VRDN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRDN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VRDN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVRDN — Frequently Asked Questions
Quick answers to the most common questions about buying VRDN stock.
Is VRDN growing earnings?
VRDN EPS is $-3.53, with earnings growth accelerating to +16.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-361M.
What are VRDN's profit margins?
Viridian Therapeutics, Inc. net margin is -483.6%, with operating margin at -512.9%. Below-average margins reflect competitive or cost pressures.
How consistent are VRDN's earnings?
VRDN earnings data spans 2012-2025. The accelerating earnings trend is +16.6% YoY. Historical data enables comparison across business cycles.